Navigation Links
23andMe demonstrates comprehensive research capabilities at annual meeting for ASHG
Date:11/5/2012

MOUNTAIN VIEW, CA -- (November 5, 2012) -- 23andMe, the leading personal genetics company, is participating in five panels and presentations, as well as hosting 17 poster presentations at this year's annual meeting of the American Society of Human Genetics (ASHG) held in San Francisco, November 6 10, 2012.

"The breadth and depth of research we are presenting at ASHG is a testament to the power of our web-based research model," 23andMe co-founder and CEO Anne Wojcicki said. "From analyzing exome data to detecting a somatic mutation associated with Myeloproliferative Neoplasms, our unique research model is delivering genetic discoveries that expand our understanding of human biology."

Panels and Presentations

  • 23andMe Senior Director of Research Joanna Mountain, PhD. will participate in a panel discussion on the role of direct-to-consumer genetics in research on Wednesday, November 7th.
  • 23andMe Senior Science Content Manager Shirley Wu, PhD. will participate in a panel discussion about how social media can be used to benefit research, also on Wednesday, November 7th.
  • 23andMe Principal Scientist of Statistical Genetics Nicholas Eriksson PhD. will give a platform presentation on more than 250 novel associations with human morphological traits on Thursday, November 8th.
  • 23andMe Computational Biologist Eric Durand, PhD. will give a platform presentation on fine scale population genetic structure of African Americans, also on Thursday, November 8th.

The full schedule of the company's presentations and posters is available online at www.23andMe.com/ashg2012.

Senior Medical Director for 23andMe, Dr. Uta Francke, will also be receiving the William Allan Award, which recognizes a scientist for substantial and far-reaching scientific contributions to human genetics.

"It is an honor to work with someon as pioneering as Dr. Francke," Wojcicki added. "We are thrilled to see the American Society of Human Genetics recognize the significant contributions Dr. Francke has made to the field."

Call for Academic Collaborators

23andMe is calling for academic collaborators to participate in the development of a new Research Portal that will, for the first time, allow researchers from outside of 23andMe to access de-identified, aggregated genotype and phenotype data from the 23andMe database.

The company believes the contributions of its customers can go further towards accelerating the discovery process if it provides qualified researchers with self-service access to 23andMe's expanding dataset within a framework that also protects the privacy of participants. Resulting discoveries can benefit not just the 23andMe community, but also expand the understanding of human genetics more broadly. Institutions interested in participating can review criteria and apply at www.23andMe.com/ResearchPortal.

The company will also have a presence in the conference exhibit hall at booth #826. Conference attendees can stop by to talk with 23andMe scientists and enter daily drawings for free Personal Genome Services a $299 value. 23andMe helps individuals explore their own DNA and provides more than 200 health and trait reports as well as genetic ancestry information through its Personal Genome Service.


'/>"/>
Contact: Catherine Afarian
cat@23andMe.com
408-656-8872
23andMe Inc.
Source:Eurekalert

Related medicine news :

1. 23andMe acquires CureTogether, Inc.
2. New Video Demonstrates Skin Cancer Self-Exam
3. Novel technique demonstrates interactions between malaria parasite and HIV
4. Published clinical trial demonstrates efficacy of Sea-Band for migraine-related nausea
5. A study demonstrates that ibuprofen improves bone repair after surgery or a fracture
6. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. Automated insulin dosage titration system demonstrates positive clinical study results
9. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
10. First comprehensive review of European breast cancer screening programs finds benefits outweigh harm
11. Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... , ... June 23, 2017 , ... MD Now ... This is MD Now’s 28th facility overall and marks the urgent care center's eighth ... one mile North of The Falls shopping mall. The new clinic offers a wide ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... on 26th June, 2017 from 9 am to 3 pm to present to graduate ... The program is an original curriculum project led by The Health Improvement Service ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... assistance and financial planning services to communities in the greater Chicago metropolitan area, ... to offer assistance to underprivileged youth in Chicago. , Founded in 1897, Hephzibah ...
(Date:6/23/2017)... Morgantown, WV (PRWEB) , ... June 23, 2017 ... ... asset protection services and personal financial planning to families and business owners in ... Stepping Stones organization to help provide services to differently abled residents in the ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: